Angel Biotechnology Holdings Plc
Angel Biotechnology Holdings plc, (AIM: ABH) the biopharmaceutical contract manufacturer, is pleased to announce the signing of a GMP Manufacturing contract with Materia Medica Holding, a leading pharmaceutical company in Russia. The contract, for process development and GMP manufacture of specific antibodies, is valued at circa £1.5M. Work on the project will commence shortly and GMP manufacturing is expected to complete in early 2012.
Commenting on the contract, Gordon Sherriff, Angel's Chief Operating Officer said: "We have worked with Materia Medica and the MHRA over a long period of time to address the complex regulatory path for this contract and we are delighted to have found innovative solutions that allow the project to progress. We are very pleased to be able to continue our commitment to working with Materia Medica and supporting regulatory compliant manufacture of its pipeline of products. Supporting clients with advanced biologics through the often complex regulatory hurdles is becoming a significant part of Angel's service offering."
Sergey Tarasov, of Materia Medica Holding R&D department, said: "We are very pleased to sign this contract with Angel. This product is key to our product portfolio and Angel's steadfastness to identify a regulatory compliant manufacturing route demonstrates the strong relationship our companies have built over the last 2.5 years. We look forward to working with Angel on future projects"
About Angel Biotechnology Holdings plc
Angel Biotechnology Holdings plc is a biomanufacturing company offering process development
services and GMP manufacturing for advanced biologics, supporting biotechnology and
pharmaceutical companies worldwide. Angel's principal activity is the manufacture and supply of
materials for use in early stage drug development and pre-clinical studies, along with drug
product and CMC documentation for Phases I, II and III clinical trials and the manufacture of
licensed drugs or vaccines. Angel specializes in the provision of advanced biologics including
autologous and allogeneic cell therapy products including stem cells and cellular vaccines,
specific purified natural and recombinant proteins and bacteriophage. Angel is managed by a
team with wide ranging experience in biopharmaceutical manufacture, gained in companies such
as Glaxo, Johnson and Johnson, Serologicals Inc., PPL Therapeutics and Intercell Ag.
For more information visit www.angelbio.com.
About Materia Medica Holding
OOO "NPF "Materia Medica Holding", founded in 1992, now is one of the top manufacturers of
homeopathic drugs in the Russian Federation and CIS countries.
Materia Medica Holding is the 6th largest Russian pharmaceutical company by sales with a focus on OTC drugs production. It is one of the major companies operating in this segment of the Russian market.
Recent successful development of a novel class of antibody-based therapeutics switched the strategic priorities of the company to manufacturing of oral ultra-low doses of antibodies produced by homeopathic technology. Patented technology, proven efficacy and safety, favorable benefit/risk ratio are the key distinctive features of novel drugs. Currently the company manufactures and markets the drugs for the treatment of many unmet medical needs: anxiety, alcohol addiction, erectile dysfunction, viral infections, benign prostate hyperplasia, rheumatoid arthritis/osteoarthritis, chronic heart failure, allergy etc.
For more information visit www.materiamedica.ru/en/.
SOURCE: Angel Biotechnology Holdings plc